» Articles » PMID: 33741515

Prolonged Viral Shedding and Antibody Persistence in Patients with COVID-19

Abstract

SARS-CoV-2 as a new global threat has affected global population for one year. Despite the great effort to eradicate this infection, there are still some challenges including different viral presentation, temporal immunity in infected individuals and variable data of viral shedding. We studied 255 COVID-19 suspected individuals to assess the viral shedding duration and also the antibody development against SARS-CoV-2 among the cases. Real Time RT-PCR assay was applied to determine the virus presence and SARS-CoV-2 antibodies were evaluated using SARS-CoV-2 IgM and IgG kits. 113 patients were confirmed for COVID-19 infection. The patients were followed until negative PCR achieved. The median viral shedding among studied population was obtained 34.16 (±17.65) days which was not significantly associated with age, sex and underlying diseases. Shiver and body pain were found in prolonged form of the infection and also patients who had gastrointestinal problems experienced longer viral shedding. Moreover, IgG was present in 84% of patients after 150 days. According to this data, the median viral shedding prolongation was 34.16 days which indicates that 14 days isolation might not be enough for population. In addition, IgG profiling indicated that it is persistent in a majority of patients for nearly 6 months which has brought some hopes in vaccine efficacy and application.

Citing Articles

Epidemiology of SARS-CoV-2 in Kakuma Refugee Camp Complex, Kenya, 2020-2021.

Ope M, Musyoka R, Kiogora J, Wambugu J, Hunsperger E, Emukule G Emerg Infect Dis. 2024; 30(5):900-907.

PMID: 38666563 PMC: 11060438. DOI: 10.3201/eid3005.231042.


Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran.

Sadat Larijani M, Biglari A, Sorouri R, Salehi-Vaziri M, Doroud D, Azadmanesh K Iran Biomed J. 2024; 28(1):1-7.

PMID: 38224028 PMC: 10994636. DOI: 10.61186/ibj.3964.


A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports.

Sadat Larijani M, Doroud D, Banifazl M, Karami A, Bavand A, Ashrafian F Eur J Med Res. 2023; 28(1):542.

PMID: 38008729 PMC: 10676592. DOI: 10.1186/s40001-023-01531-7.


Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.

Eybpoosh S, Biglari A, Sorouri R, Ashrafian F, Sadat Larijani M, Verez-Bencomo V PLoS Pathog. 2023; 19(11):e1011744.

PMID: 37910480 PMC: 10619776. DOI: 10.1371/journal.ppat.1011744.


Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine.

Farahmand B, Sadat Larijani M, Fotouhi F, Biglari A, Sorouri R, Bagheri Amiri F Heliyon. 2023; 9(10):e20555.

PMID: 37810803 PMC: 10551543. DOI: 10.1016/j.heliyon.2023.e20555.


References
1.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

2.
Jung C, Park H, Kim D, Lim H, Chang J, Choi Y . Association between Body Mass Index and Risk of Coronavirus Disease 2019 (COVID-19): A Nationwide Case-control Study in South Korea. Clin Infect Dis. 2020; 73(7):e1855-e1862. PMC: 7499566. DOI: 10.1093/cid/ciaa1257. View

3.
Salehi-Vaziri M, Jalali T, Farahmand B, Fotouhi F, Banifazl M, Pouriayevali M . Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: a case series from Iran. Eur J Clin Microbiol Infect Dis. 2021; 40(8):1713-1719. PMC: 7972329. DOI: 10.1007/s10096-021-04221-6. View

4.
Iwasaki A . What reinfections mean for COVID-19. Lancet Infect Dis. 2020; 21(1):3-5. PMC: 7550040. DOI: 10.1016/S1473-3099(20)30783-0. View

5.
Henry B, Lippi G . Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020; 52(6):1193-1194. PMC: 7103107. DOI: 10.1007/s11255-020-02451-9. View